Innate Pharma Presents Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022

MARSEILLE, France–(BUSINESS WIRE)–Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “company”) announced today that the following presentations will be presented at the 2022 ESMO (European Society for Medical Oncology) Annual Meeting, being held September 9-13, 2022 in Paris, France.

  • A phase Ib, multicenter study to evaluate the safety and efficacy of lacutamab in patients with relapsed/refractory peripheral T-cell lymphoma expressing KIR3DL2

    – Abstract number: 647TiP

    – Session Type: Trial In Progress Poster

    – Session title: Hematological Malignancies

    – Session date: Sunday 11 September 2022

    – Presenter: Marianna Muller, MD, PharmD, Director of Clinical Development at Innate Pharma
  • Lecture: Design of multispecific antibodies: ANKET for antigen-specific activation of NK cells

    – Session type: special session

    – Session title: New Frontiers in Drug Discovery

    – Date and time: Monday, September 12, 2022, 9:05 – 9:20 a.m. CEST

    – Location: 7.3.U – Urval Auditorium

    – Presenter: Eric Vivier, DVM, PhD, Chief Scientific Officer of Innate Pharma
  • Oral Presentation: Platform study of neoadjuvant durvalumab (D) alone or in combination with novel agents in patients (PT) with resectable early-stage non-small cell lung cancer (NSCLC): pharmacodynamic correlates and dynamics of circulating tumor DNA (ctDNA) in the NeoCOAST study [AstraZeneca-sponsored]

    – Presentation #929MO

    – Session type: Mini oral session

    – Session title: Non-metastatic NSCLC and other thoracic malignancies

    – Date and time: Monday, September 12, 2022 at 15:15 CEST

    – Location: 7.3.O – Orléans Auditorium

    – Presenter: Jonathan Spicer (Montreal, Canada)

The poster and presentations will be available after the presentation in the publications section of

About lacutamab:

Lacutamab (IPH4102) is a first humanized anti-KIR3DL2 antibody that induces cytotoxicity currently in clinical trials for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease, and peripheral T-cell lymphoma ( PTCL) is located. Rare cutaneous T-lymphocyte lymphomas have a poor prognosis with few effective and safe therapeutic options in advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family that is expressed by approximately 65% ​​of patients of all CTCL subtypes and by up to 90% of patients with certain aggressive CTCL subtypes, particularly Sézary syndrome. It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has restricted expression on normal tissues.

About ANKET:

ANKET (Abody based NK cell Erodent Therapeutics) is Innate’s proprietary platform for the development of next-generation multispecific natural killer (NK) cells to treat certain types of cancer.

This versatile, fit-for-purpose technology creates an entirely new class of molecules to induce synthetic immunity against cancer. It takes advantage of harnessing NK cell effector functions against cancer cells and also delivers proliferation and activation signals targeted to NK cells.

Our latest innovation, the tetraspecific ANKET molecule, is the first NK cell agger technology that targets activating receptors (NKp46 and CD16), a tumor antigen and an interleukin-2 receptor (via an IL-2 variant, IL- 2v) activates a single molecule.

About Monalizumab:

Monalizumab is a potential first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells.

NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves from being killed by NKG2A+ immune cells. HLA-E is frequently overexpressed in the cancer cells of many solid tumors and hematologic malignancies. Monalizumab can restore a broad anti-tumor response mediated by NK and T cells and potentiate the cytotoxic potential of other therapeutic antibodies1.

Ongoing development of monalizumab is focused on evaluating monalizumab in various combination strategies in various malignancies, including the Phase 3 PACIFIC-9 study in adults with locally advanced (Stage III), unresectable NSCLC who have not progressed platinum-based concomitant chemoradiotherapy for early-stage lung cancer and the phase 2 NeoCOAST-2 study in early-stage neoadjuvant NSCLC.

About Innate Pharma:

Innate Pharma SA is a global, clinical-stage oncology-focused biotechnology company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s broad antibody pipeline includes several potentially first-in-class clinical and preclinical candidates for cancers with high unmet medical needs.

Innate is a pioneer in understanding the biology of natural killer cells and has expanded his expertise in tumor microenvironment and tumor antigens as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and significant alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi and a multi-product collaboration with AstraZeneca.

Headquartered in Marseille, France and with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at

About Innate Pharma Shares:

ISIN code


ticker code

Euronext:IPH Nasdaq:IPHA



Disclaimer Regarding Forward-Looking Information and Risk Factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect,” and “will” and similar expressions, are intended to identify forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to the safety, progress and results of its ongoing and planned clinical and preclinical studies, regulatory review and approval of its product candidates and commercialization efforts of the Company and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties that could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please see the “Facteurs de Risque” section. the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website or on Innate Pharma’s website, as well as public filings and reports filed at with the US Securities and Exchange Commission (“SEC”), including the Company’s annual report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC or otherwise published by the company.

This press release and the information contained herein does not constitute an offer to sell or the solicitation of an offer to purchase or subscribe for shares in Innate Pharma in any country.

1 André et al., Cell 2018

Comments are closed.